Brief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
05/10/2026 13:16
BRIEF-Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial Oct 5 (Reuters) - Anixa Biosciences Inc ANIX.O:
ANIXA BIOSCIENCES ANNOUNCES FIRST CASE OF STABLE DISEASE FOR THREE MONTHS IN OVARIAN CANCER CAR-T CLINICAL TRIAL
ANIXA BIOSCIENCES - FIRST PATIENT IN CURRENT COHORT SHOWS NO CANCER PROGRESSION THREE MONTHS AFTER TREATMENT
ANIXA BIOSCIENCES - MULTIPLE PATIENTS IN TRIAL HAVE SURVIVED MORE THAN ONE YEAR, INCLUDING ONE BEYOND TWO YEARS
ANIXA BIOSCIENCES - NO DOSE-LIMITING TOXICITIES OBSERVED TO DATE IN CAR-T TRIAL
Source text: ID:nPn50S3xha
Further company coverage: ANIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anixa Biosciences
See all newsBrief: Anixa Biosciences Announces First Case Of Stable Disease For Three Months In Ovarian Cancer Car-T Clinical Trial
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Anixa Biosciences Inc reports results for the quarter ended July 31 - Earnings Summary
Anixa Biosciences Inc expected to post a loss of 9 cents a share - Earnings Preview
Factbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine